[Special Stock] Hwail Yakpum Rises on Dexmethasone Raw Material Production Amid COVID-19 Resurgence

[Asia Economy Reporter Hyunseok Yoo] Hwail Pharm is showing strong performance. As the number of new domestic COVID-19 cases increases, the production of the raw material for 'Dexamethasone,' used as a treatment for COVID-19, has gained attention.

As of 9:50 AM on the 16th, Hwail Pharm was trading at 13,650 KRW, up 4.20% (550 KRW) compared to the previous trading day.

Domestic quarantine authorities prescribe Dexamethasone or Remdesivir to severe COVID-19 patients. Dexamethasone suppresses excessive immune and inflammatory responses such as cytokine storms, protecting organs like the lungs.

Additionally, Hwail Pharm is known to supply 'Entecavir,' the raw material for hepatitis B treatment.

Recently, domestic pharmaceutical companies have been developing treatments for COVID-19 by 'repurposing' drugs for pancreatitis and hepatitis B.

Meanwhile, according to the Central Disease Control Headquarters, as of midnight today, the number of new domestic COVID-19 cases was 848, with a cumulative total of 44,364 cases.